Predict your next investment

HEALTHCARE | Drug Development
lagunarx.com

See what CB Insights has to offer

Stage

Dead | Dead

Total Raised

$36.23M

About Laguna Pharmacueticals

Laguna Pharmaceuticals, formerly known as ChanRx, is a biopharmaceutical company advancing vanoxerine for treatment of atrial fibrillation and atrial flutter.

Laguna Pharmacueticals Headquarter Location

4225 Executive Square

Cleveland, Ohio, 44128,

United States

216-223-8778

Latest Laguna Pharmacueticals News

Rechristened Laguna Pharmaceuticals Raises $30M, Moves To San Diego

Feb 17, 2015

Laguna Pharmaceuticals, founded in 2006 as a spinout of Cleveland, OH-based drug discovery and testing company ChanTest, has raised $30 million in a Series B round of venture funding and relocated in San Diego. The company, previously known as ChanRx, also recruited former Amira Pharmaceuticals CEO Bob Baltera as CEO. Versant Ventures and Frazier Healthcare led the $30-million round, which was joined by existing investor Santé Ventures. The round is expected to fund a late-stage clinical trial of Laguna’s lone drug, a 1,4-dialkylpiperazine derivative (Vanoxerine). The drug is intended to treat atrial fibrillation, an irregular heartbeat estimated to currently affect about 2.3 million Americans. The company raised $5 million in 2011 from Santé Ventures and ChanTest founder and CEO Arthur “Buzz” Brown. ChanTest began in 1998 to provide testing services to help pharmaceutical and biotech companies assess cardiac risk early in the process of drug development. Boston’s Charles River Laboratories acquired ChanTest for $54 million at the end of October. While several drugs are currently available for treating heart arrhythmias, Laguna says current drug options are limited by poor efficacy and toxicity. In results from a mid-stage trial reported in late 2013 , the company said 76 percent of the patients given the highest oral dose (400 mg) of Vanoxerine converted to a normal heart rhythm within 8 hours, and 84 percent converted within 24 hours—a rate approaching that of the electrical shock treatment known as direct current cardioversion. In Baltera, Laguna gets a veteran CEO. The job at Laguna is his first CEO position since 2011, when he led the sale of Amira to Bristol-Myers Squibb (NYSE: [[ticker:BMY) for $325 million in cash, with an additional $150 million tied to meeting certain development milestones. At the time, Amira’s lead drug was a compound targeting pulmonary fibrosis, which Amira had advanced only through early stage clinical trials. Baltera successfully exempted two other drug candidates from the BMS deal, and a new company called Panmira Pharmaceuticals was established to advance development of those compounds. Baltera will be joining Laguna’s co-founder and chief medical officer, Howard Dittrich, who worked previously at NovaCardia and other cardiovascular companies. “This is about commercialization, it’s not about proof of concept,” Baltera told me in a recent phone interview. Laguna “is going to be a lean, mean, product development and commercialization machine.” Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @bvbigelow Share or Leave a Comment

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Laguna Pharmacueticals Patents

Laguna Pharmacueticals has filed 5 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/25/2014

Cardiac arrhythmia, Stimulants, Piperazines, Cardiac electrophysiology, Dopamine reuptake inhibitors

Application

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/25/2014

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Cardiac arrhythmia, Stimulants, Piperazines, Cardiac electrophysiology, Dopamine reuptake inhibitors

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Application

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.